Document is current

Article History

Received: 10 April 2022

Accepted: 29 September 2022

First Online: 5 November 2022

Declarations

:

: Financial interests: Dr. Shima received personal fees from AstraZeneca and Ono Pharmaceutical outside the submitted work during the study period. Dr. Sato received personal fees from AstraZeneca, Chugai Pharmaceutical, MSD, Ono Pharmaceutical, Novartis, Pfizer, Taiho Pharmaceutical, Nippon Kayaku, Bristol Myers Squibb, Eli Lilly, Takeda, and Kyowa Kirin, outside the submitted work. Dr. Morimoto received lecturers’ fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Toray, Tsumura; manuscript fees from Bristol-Myers Squibb and Kowa; advisory board for Novartis. Dr. Hirabayashi recieved personal fees from AstraZeneca. Dr. Tachikawa received personal fees from AstraZeneca and Ono Pharmaceutical. Dr. Tomii received honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Ono Pharmaceutical, Eli Lilly, Kyorin, Kyowa Hakko Kirin, MSD, Taiho Pharmaceutical, Nippon Kayaku, Pfizer and Bristol Myers Squibb. The remaining authors have no conflicts of interest to declare. Non-financial interests: All authors have no conflict of interest to declare as non-financial interests.

: This study was approved by the Kobe City Medical Center General Hospital Ethics Committee of Kobe City Medical Center General Hospital as the number of zn180632.

: Informed consent was obtained from the patients to use pathological specimens, but informed consent to use the clinical information was waived.

: The authors affirmed that participants agreed with publication of the Supplementary Fig. 2 in Online Resource 3.